ABCG2 and triple-negative breast carcinoma: Moreover, MAGL inhibitor JJKK048 was shown to reduce hypoxia-induced resistance to multi-kinase inhibitor regorafenib in triple negative breast cancer cells by downregulating ABCG2 transporter expression, and thus reducing the cellular export of the anticancer drug [31].